DETECTION OF NUCLEIC ACID SEQUENCE DIFFERENCES USING COUPLED LIGASE DETECTION AND POLYMERASE CHAIN REACTIONS - The present invention relates to a method for identifying a target nucleotide sequence. This method involves forming a ligation product on a target nucleotide sequence in a ligation detection reaction mixture, amplifying the ligation product to form an amplified ligation product in a polymerase chain reaction (PCR) mixture, detecting the amplified ligation product, and identifying the target nucleotide sequence. Such coupling of the ligase detection reaction and the polymerase chain reaction permits multiplex detection of nucleic acid sequence difference.

2012-10-04

20120252697

TRANSFORMED HUMAN PLURIPOTENT STEM CELLS AND ASSOCIATED METHODS - The present disclosure provides transformed human pluripotent stem cell (t-hPSC). t-hPSCs are not dependent on Oct4 for renewal and survival, however exhibit a sensitivity to reduced levels of the transcription factor Nanog. Also provided are methods of culturing cells for use in a cell-based screening assay comprising placing one or more transformed human pluripotent stem cells into a receptacle and culturing said stem cells in the receptacle to form a monolayer of stem cells without cell overlap. Methods of screening compounds using t-hPSCs are also described.

COUPLED RECOGNITION/DETECTION SYSTEM FOR IN VIVO AND IN VITRO USE - The present invention relates to novel fluorophores and their use in combination with novel nucleic acid molecules, called aptamers, that bind specifically to the fluorophore and thereby enhance the fluorescence signal of the fluorophore upon exposure to radiation of suitable wavelength. Molecular complexes formed between the novel fluorophores, novel nucleic acid molecules, and their target molecules are described, and the use of multivalent aptamer constructs as fluorescent sensors for target molecules of interest are also described.

2012-10-04

20120252700

DETECTION OF NUCLEIC ACID SEQUENCE DIFFERENCES USING THE LIGASE DETECTION REACTION WITH ADDRESSABLE ARRAYS - The present invention describes a method for identifying one or more of a plurality of sequences differing by one or more single base changes, insertions, deletions, or translocations in a plurality of target nucleotide sequences. The method includes a ligation phase, a capture phase, and a detection phase. The ligation phase utilizes a ligation detection reaction between one oligonucleotide probe, which has a target sequence-specific portion and an addressable array-specific portion, and a second oligonucleotide probe, having a target sequence-specific portion and a detectable label. After the ligation phase, the capture phase is carried out by hybridizing the ligated oligonucleotide probes to a solid support with an array of immobilized capture oligonucleotides at least some of which are complementary to the addressable array-specific portion. Following completion of the capture phase, a detection phase is carried out to detect the labels of ligated oligonucleotide probes hybridized to the solid support.

2012-10-04

20120252701

METHODS FOR GENERATING POLYNUCLEOTIDES HAVING DESIRED CHARACTERISTICS BY ITERATIVE SELECTION AND RECOMBINATION - A method for DNA reassembly after random fragmentation, and its application to mutagenesis of nucleic acid sequences by in vitro or in vivo recombination is described. In particular, a method for the production of nucleic acid fragments or polynucleotides encoding mutant proteins is described. The present invention also relates to a method of repeated cycles of mutagenesis, shuffling and selection which allow for the directed molecular evolution in vitro or in vivo of proteins.

2012-10-04

20120252702

PROCESSING OF AMPLIFIED DNA FRAGMENTS FOR SEQUENCING - A processing method to trim ends of DNA fragments, exposing the internal DNA part to give original DNA sequence information enabling application of next generation sequencing for DNA samples to be amplified by DOP-PCR or other primer dependent amplification methods. Specifically, nucleic acids are amplified using primers comprising a recognition site for a restriction enzyme, for example Bpml or Mmel. Primer sequences are removed by cleavage with the restriction enzyme.

2012-10-04

20120252703

METHOD AND SYSTEM FOR CAPTURE AND USE OF INTACT VESICLES ON ELECTRODEPOSITED HYDROPHOBICALLY MODIFIED BIOPOLYMER FILMS - A biosensor comprising an electrically conductive substrate coated with a modified chitosan biopolymer that has been electrodeposited on the substrate, wherein said modified chitosan biopolymer comprises at least one vesicle binding molecule. The biosensor is manufactured by a method where a modified chitosan biopolymer is electrodeposited on a substrate. The method is also used to manufacture a modified chitosan biopolymer film by electrodeposition of the chitosan on the substrate and later removing the film from the substrate after electrodeposition. The resulting film can be used in bandages to treat various types of wounds. The biosensor can also be used to detect various analytes in samples.

2012-10-04

20120252704

BIOANALYTICAL INSTRUMENTATION USING A LIGHT SOURCE SUBSYSTEM - The invention relates to a light source for irradiating molecules present in a detection volume with one or more selected wavelengths of light and directing the fluorescence, absorbance, transmittance, scattering onto one or more detectors. Molecular interactions with the light allow for the identification and quantitation of participating chemical moieties in reactions utilizing physical or chemical tags, most typically fluorescent and chromophore labels. The invention can also use the light source to separately and simultaneously irradiate a plurality of capillaries or other flow confining structures with one or more selected wavelengths of light and separately and simultaneously detect fluorescence produced within the capillaries or other flow confining structures. In various embodiments, the flow confining structures can allow separation or transportation of molecules and include capillary, micro bore and milli bore flow systems. The capillaries are used to separate molecules that are chemically tagged with appropriate fluorescent or chromophore groups.

2012-10-04

20120252705

Treatment Fluids Comprising Vitrified Shale and Methods of Using Such Fluids in Subterranean Formations - Non-settable spacer fluids for use in subterranean operations comprising: a base liquid; vitrified shale; a chelating agent; a clay weighting agent; and a viscosifying agent. The chelating agent includes one or more of nitrilotriacetic acid, ethylene diamine tetracetic acid (EDTA), ethylene glycol tetraacetic acid (EGTA), tartaric acid, a polycarboxylic acid, a lignosulphonate, hydroxyethylidene diphoshponic acid (HEDP), diethylene triamine penta (methylene phosphonic) acid (DETMP), amino-tri-methylene phosphonic acid (ATMP), ethylene diamine tetra (methylene phosphonic) acid (EDTMP), or salts thereof. The clay weighting agent is present in the range of about 0.01% to about 85% by weight of the spacer fluid. The viscosifying agent is present in the range of about 1% to about 10% by weight of the spacer fluid.

2012-10-04

20120252706

WELL TREATMENT COMPOSITES FOR USE IN WELL TREATMENT FLUIDS - A well treatment composite comprising a well treatment agent adsorbed onto a water-insoluble adsorbent may be prepared by precipitating the well treatment agent, in the presence of a metal salt, from a liquid while the well treatment agent is being adsorbed onto the water-insoluble adsorbent. After a treatment fluid containing the composite is introduced into a well or a subterranean formation, the well treatment agent is slowly released from the composite. The composite permits a continuous supply of the well treatment agent into a targeted area and is particularly effective in high pH treatment fluids.

2012-10-04

20120252707

METHODS AND COMPOSITIONS TO DELAY VISCOSIFICATION OF TREATMENT FLUIDS - The current application discloses a method of treating a portion of a subterranean formation comprises providing a treatment fluid comprising a carrier fluid, a non-hydrolyzed polyacrylamide or a nonhydrolyzed non ionic copolymer of acrylamide, and a delaying agent; and treating the subterranean formation.

2012-10-04

20120252708

COATED PARTICLES OF A GLUTAMIC ACID N,N-DIACETATE CHELATING AGENT - Process to prepare coated particles containing a particle and a coating, wherein the particle contains glutamic acid N,N-diacetic acid or a (partial) salt thereof of the formula HnYm-GLDA, wherein Y is a cation selected from the group of sodium, potassium, lithium, and mixtures thereof, n+m=4, in which the particle is made from a solution containing glutamic acid N,N-diacetic acid or a partial salt thereof that has a p H of between 4 and 11, and subsequently or simultaneously the coating is applied on the particle, to an intermediate particle of HnYm-GLDA, wherein n is 0.1-3.2 and m is 0.8-3.9, the coated particle obtainable with the process, and the use thereof.

2012-10-04

20120252709

VESSELS, CONTACT SURFACES, AND COATING AND INSPECTION APPARATUS AND METHODS - Methods for processing a contact surface, for example to provide a gas barrier or lubricity or to modify the wetting properties on a medical device, are disclosed. First and second PECVD or other contact surface processing stations or devices and a contact surface holder comprising a contact surface port are provided. An opening of the contact surface can be seated on the contact surface port. The interior contact surface of the seated contact surface can be processed via the contact surface port by the first and second processing stations or devices. contact surface barrier, lubricity and hydrophobic coatings and coated contact surfaces, for example syringes and medical sample collection tubes are disclosed. A contact surface processing system and contact surface inspection apparatus and methods are also disclosed.

CREAMY CLEANSING COMPOSITIONS - A creamy cleansing composition including from about 0.5% to about 1.2% polymeric emulsifier; from about 0.5% to about 4% water insoluble oil; from about 1% to about 4% fatty alcohol; and greater than 92% water is described.

2012-10-04

20120252712

Gel-Form Preparations - The invention relates to gel-form agents, containing, based on the total weight of the agent, from 45 to 90 wt % of water; from 5 to 35 wt % of emulsifiers and from I to 25 wt % of surfactants as well as optionally further auxiliaries and additives. The gel-form agents have a viscous damping factor Q

2012-10-04

20120252713

COMPOSITION FOR SURFACE TREATMENT AND PROCESS - These disclosures relate to a composition comprising a combination of chemicals and to a process for using the same composition. This process provides a means to use the composition in cleaning floors and surfaces previously coated with a wax coating for protection of the surface. The composition can include a combination of chemicals selected from microemulsion concentrates based on benzyl alcohol in combination with aqueous ammonia solution.

2012-10-04

20120252714

Liquid Cleaning Compositions Containing Sulfonated Estolides and Polymeric Foam Builders - Liquid cleaning compositions are described that comprise sulfo-estolides (SE) and cationic polymers, wherein the cationic polymers serve to increase the foam volume of the liquid cleaning composition compared to a sulfo-estolide-containing composition that does not contain the cationic polymer. The liquid cleaning compositions can be used in machine and hand-laundering applications where high foam volume is desired.

2012-10-04

20120252715

Dissolvable, Personal Cleansing Compositions - A solid, dissolvable cleansing composition is disclosed. The cleansing composition includes a viscosity of about 1,000,000 to about 50,000,000 Pascal-seconds (PaS). The cleansing composition comprises about 25% or more, by weight of the cleansing composition, of a surfactant with an active content of about 60% or greater and about 5% or more, by weight of the cleansing composition, of a co-surfactant. The cleansing composition further includes about 30% or more, by weight of the cleansing composition, of expandable microspheres.

CONJUGATES OF BIOLOGICALLY ACTIVE PROTEINS HAVING A MODIFIED IN VIVO HALF-LIFE - Disclosed are biologically active protein conjugates that comprise a biologically active polypeptide coupled via a peptide bond to a polypeptide comprising from 2 to about 500 units of a repeating peptide motif, wherein the biologically active protein conjugate exhibits a modified plasma half-life compared to the intrinsic half-life of the unconjugated biologically active polypeptide or protein. Also disclosed are methods of making and using the conjugated proteins, as well as methods for determining whether a given conjugate exhibits a modified half life relative to the intrinsic half life of the unconjugated polypeptide.

2012-10-04

20120252718

Compositions and Methods for Regulating Cytochrome c-Mediated Apoptosis by tRNA - The invention relates to the discovery that tRNA is a potent regulator of cell survival, tRNA regulates the interaction between cytochrome c and Apaf-1 and subsequently Apaf-1 oligomerization into an apoptosome which in turn recruits and oligomerizes the caspase cascade which ultimately leads to cell death. Accordingly, the present invention provides compositions and methods for regulating cell survival.

COMPOSITIONS FOR TREATMENT OF EAR DISORDERS AND METHODS OF USE THEREOF - The present invention relates to compositions and methods useful for the treatment of ear disorders, administered to a treated ear in the form of a foam or a mousse. Administering a medicament in such forms will increase the residence time of the medicament in the ear canal, provide relatively uniform distribution of the composition, and can increase the penetration of the active pharmaceutical ingredient in the affected area, may release active substances slowly, enhance treatment effectiveness, increase compliance and is more convenient to use than currently available ear medications. The administration in the form of a foam or a mousse may preferably be provided as a metered dose, of a volume suitable to fill the ear canal.

METAL-BINDING THERAPEUTIC PEPTIDES - The present invention is related methods of delivering MBD peptide-linked agents into live cells. The methods described herein comprise contacting MBD peptide-linked agents to live cells under a condition of cellular stress. The methods of the invention may be used for therapeutic or diagnostic purposes.

2012-10-04

20120252723

Regulating the Amino Acid Pool Used for the Acute-Phase Protein Synthesis - The present invention is directed at a combination of (i) serine, (ii) cysteine, (iii) arginine and (iv) at least one branched amino acid, for use in the therapeutic or prophylactic treatment of inflammation or infection, wherein the combination is to be administered enterally and at a combination of (i) serine, (ii) cysteine, (iii) arginine and (iv) at least one branched amino acid, for use in the therapeutic or prophylactic treatment of an imbalance in the metabolic use of amino acid resources from the body or from nutrition in a subject having an inflammation or an infection, wherein the combination is to be administered enterally.

2012-10-04

20120252724

INSULIN PREPARATIONS CONTAINING METHIONINE - The invention relates to an aqueous pharmaceutical formulation having insulin, an insulin analog, or an insulin derivative, and methionine; and to the production thereof, to the use thereof for treating diabetes mellitus, and to a medication for treating diabetes mellitus.

2012-10-04

20120252725

USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS - The invention provides 1,3-diphenylprop-2-en-1-one derivatives and pharmaceutical compositions comprising the same for treating liver disorders, in particular those requiring the reduction of plasma level of biochemical markers such as amino-transferases. The 1,3-diphenylprop-2-en-1-one derivatives of General Formula (I) have hepatoprotective properties and can be used in methods for treating liver disorders involving the pathological disruption, inflammation, degeneration, and/or proliferation of liver cells, such as liver fibrosis or fatty liver disease.

2012-10-04

20120252726

NOVEL NEUROTROPHIC FACTORS - The invention relates to neublastin neurotrophic factor polypeptides, nucleic acids encoding neublastin polypeptides, and antibodies that bind specifically to neublastin polypeptides, as well as methods of making and methods of using the same.

PLATELET AGGREGATION INHIBITORS - Peptides and cyclized analogs thereof that are useful as platelet aggregation inhibitors in the treatment of cardiac disease, including acute coronary syndrome are disclosed.

2012-10-04

20120252731

Co-Administration of An Agent Linked to an Internalization Peptide With an Anti-Inflammatory - The invention provides methods of delivering pharmacologic agents linked to an internalization peptide, in which an inflammatory response inducible by the internalization peptide is inhibited by co-administration of an anti-inflammatory or by linking the internalization peptide to biotin or similar molecule. Such methods are premised in part on the results described in the examples whereby administration of a pharmacological agent linked to tat at high dosages is closely followed by an inflammatory response, which includes mast cell degranulation, histamine release and the typical sequelae of histamine release, such as redness, heat, swelling, and hypotension.

2012-10-04

20120252732

ALBUMIN FUSION PROTEINS - The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

2012-10-04

20120252733

USE OF TARGETED NITROXIDE AGENTS IN BONE HEALING - Provided herein are compositions and related methods useful for accelerating bone healing and growth. The compounds comprise a nitroxide-containing group attached to a mitochondria-targeting group. The compounds can be cross-linked into dimers without loss of activity.

2012-10-04

20120252734

INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II MOLECULES - The present invention relates to compounds, pharmaceutical compositions containing such compounds and methods for their use. In particular, the compounds of the invention are useful for the treatment or prevention of diseases associated with T cell proliferation such as autoimmune diseases and disorders.

Methods for Diagnosing and Treating Cancer - The invention provides methods for decreasing one or more symptoms of cancer in a patient requiring the steps of determining the activation or inactivation of the MK2 signaling pathway and, based on these determinations, administering either a MK2 inhibitor or a combination of a MK2 inhibitor and a chemotherapeutic agent, or a chemotherapeutic agent to the patient. The invention further provides methods for identifying a cancer patient that may selectively benefit from the administration of a chemotherapeutic agent, or the administration of a MK2 inhibitor or the combination of a MK2 inhibitor and a chemotherapeutic agent, requiring the steps of determining the activation or inactivation of the MK2 signaling pathway. The invention additionally provides methods and kits for diagnosing a chemotherapy-sensitive or chemotherapy-resistant cancer in a subject that require the step of (or reagents for) determining the activation or inactivation of the MK2 signaling pathway. The invention also provides methods of treating a cancer patient diagnosed as having a chemotherapy-sensitive or a chemotherapy-resistant cancer.

2012-10-04

20120252738

Tubulin Inhibitors - The present invention relates to novel tubulin binding molecules of formula (I) and their use for the treatment of cancer and other diseases.

2012-10-04

20120252739

Tubulin Inhibitors - The present invention relates to novel tubulin binding molecules of formula (I) and their use for the treatment of cancer and other diseases.

2012-10-04

20120252740

HDAC INHIBITORS AND THERAPEUTIC METHODS OF USING SAME - Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a neurological disease, traumatic brain injury, stroke, malaria, an autoimmune disease, autism, and inflammation, also are disclosed.

2012-10-04

20120252741

NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS - Provided herein are semi-synthetic glycopeptides having antibacterial activity. The semi-synthetic glycopeptides described herein are made by chemical modification of a glycopeptide by hydrolyzing the disaccharide moiety of the amino acid-4 of the parent glycopeptide in acidic medium to give the amino acid-4 monosaccharide; conversion of the monosaccharide to the amino-sugar derivative; acylation of the amino substituent on the amino acid-4 amino-substituted sugar moiety with certain acyl groups; conversion of the amide group in amino acid-3 to various acylamide, acylsulfonamide, acylsulfonylurea derivatives; aminomethylation with substituent containing sulfonamide or acylsulfonamide group on amino acid-7 through Mannich reaction; and conversion of the acid moiety on the macrocyclic ring to certain substituted amides. Also provided herein are pharmaceutical compositions comprising the semi-synthetic glycopeptides, and methods of use of the semi-synthetic glycopeptides for the treatment and/or prophylaxis of diseases, especially bacterial infections.

2012-10-04

20120252742

Human Single-Chain T Cell Receptors - A soluble human single-chain T cell receptor (TCR) having the structure: Vα2-L-Vβ or Vβ-L-Vα2, wherein L is a linker peptide that links Vβ with Vα, Vβ is a TCR variable β region, and Vα2 is a TCR variable α region of the family 2 is provided. The provided scTCR is useful for many purposes, including the treatment of cancer, viral diseases and autoimmune diseases.

METHODS AND COMPOSITIONS FOR DETERMINING THE RESPONSIVENESS OF CANCER THERAPEUTICS - The present invention relates to methods for predicting the responsiveness of a patient to a breast cancer treatment regimen by assaying a biological sample to determine the level of expression of the long-chain fatty acyl-CoA synthetase 4 (ACSL4) in the biological sample. The present invention also provides ACSL4 inhibitors and uses of ACSL4 inhibitors as adjuvant therapies in breast cancer treatment regimens.

2012-10-04

20120252749

Methods of Treating Cancer with Glut Inhibitors - Methods of treating cancer comprising administering inhibitors of glucose transporters (GLUTs) are provided. Methods of predicting whether a cancer will respond to treatment with a GLUT inhibitor also are provided.

2012-10-04

20120252750

FORMULATIONS FOR REDUCING NEURONAL DEGENERATION - Nutriceutical and pharmaceutical formulations for treating neurodegenerative disorders such as Alzheimer's disease are provided. Nutriceutical formulations include two or more of folate, vitamin E, and acetyl-L-carnitine (ALCAR). Pharmaceutical formulations include two or more of 3-deaza-adenosine (DZA), N-acetyl-L-cysteine (NAC), and S-adenosylmethionine (SAM).

THERAPEUTIC TARGET FOR PANCREATIC CANCER CELLS - This invention provides a therapeutic target for pancreatic cancer. The invention further provides methods of screening of new therapeutic agents using the target. The invention also provides a pharmaceutical composition comprising fasudil or derivatives thereof for pancreatic cancer treatment, and a kit comprising such a pharmaceutical composition.

2012-10-04

20120252754

Candy Cakes - Hyperkalemic Periodic Paralysis is a disease in mainly stock type horses that can be treated by giving the horse light corn syrup. Currently, the easiest way to do this is with a syringe, which is actually very difficult. The invention is a treat that will deliver a specific amount of light corn syrup per treat. This makes the entire process of delivering the corn syrup easier, faster, cleaner, and actually enjoyable for the horse. The treat can be used as an abortive measure, and also as a preventative measure if the owner incorporates the treat into the horses' daily routine. In addition to being used as the treatment for the disease, it can also be used as a regular treat for HYPP positive horses.

2012-10-04

20120252755

COMPOSITIONS AND METHODS FOR DISINFECTING MATERIALS - The present invention relates to methods for disinfecting or decontaminating a material or for preventing an infection or contamination of a material. The invention further relates to compositions which are suitable for disinfecting a material or for preventing an infection or contamination of a material and to uses of such compositions. The invention further relates to a medical use of chitosan and to a pharmaceutical composition comprising the chitosan. The invention further relates to a method of treating a microbial infection and to an aqueous solution comprising chitosan. The invention moreover relates to a chitosan or a pharmaceutical composition comprising a chitosan for an epithelial cell growth stimulating treatment of a patient's tissue and to a method of stimulating the growth of epithelial cells. The invention also relates to a tissue dressing material.

2012-10-04

20120252756

Pharmaceutical Compositions and Methods for Treating, Controlling, Ameliorating, or Reversing Conditions of the Eye - A pharmaceutical composition comprises a polyethylene glycol having a molecular weight in the range from about 1,000 to about 10,000, and a water-soluble cellulose derivative having a molecular weight in the range from about 50,000 to 120,000. The composition can further comprise boric acid and/or phosphate, a non-ionic surfactant, and/or an ophthalmic therapeutic agent. The composition is effective in treating, controlling, ameliorating, or reversing one or more conditions or symptoms of dry eye.

NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES - The invention relates to novel pyrido[2,3-b]pyrazine derivatives of the general formulae (I) and (II), and to their preparation and use as medicaments, especially for the treatment of malignant disorders and other disorders based on pathological cell proliferations.

2012-10-04

20120252761

KINASE INHIBITORS - Compounds are provided for use with kinases that comprise a compound selected from the group consisting of:

2012-10-04

20120252762

ANTI-CANCER AGENT - The anti-cancer agent of the present invention contains at least one kind of phosphine transition metal complex selected from a group of compounds represented by the following Formulae (1a) to (1d). According to this anti-cancer agent, an anti-cancer agent is provided which has a higher anti-cancer activity and lower toxicity compared to anti-cancer agents in the related art. In Formulae (1a), (1b), (1c), and (1d), R

2012-10-04

20120252763

NOVEL GROUP OF STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL PATHWAY INHIBITORS - The present invention relates to the use of a novel class of cancer stem cell pathway (CSCP) inhibitors; to methods of using such compounds to treat refractory, recurrent, or metastatic cancers; to methods of selective killing cancer cells by using such compounds with specific administration regimen; to methods of targeting cancer stem cells by inhibiting Stat3 pathway; to methods of using novel compounds in the treatment of conditions or disorders in a mammal related to aberrant Stat3 pathway activity; and to processes for preparing such compounds and intermediates thereof, and to the pharmaceutical composition of relevant compounds, and to the specific methods of administration of these compounds.

2012-10-04

20120252764

COMPOSITIONS AND METHODS FOR PROTECTING CELLS FROM TOXIC EXPOSURES - The present invention provides compositions and methods for protecting cells and tissues from damage associated with therapeutic treatments of cancers and other diseases and conditions where reactive oxygen species are produced. The present invention also provides compositions useful as research reagents.

Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens - The present invention provides ascending-dose extended cycle regimens in which a female is administered an estrogen and a progestin for a period of greater than 30 or 31 consecutive days, optionally followed by a hormone-free period or by a period of administration of estrogen. The disclosed regimens can be administered to a female to provide contraceptive and non-contraceptive benefits.

2012-10-04

20120252768

COMPOSITION CONTAINING PROTOPANAXATRIOL AND PROTOPANAXADIOL - A composition including: at least one mixture selected from the group consisting of a mixture of (A) panaxatriol and (B) protopanaxatriol and a mixture of (C) panaxadiol and (D) protopanaxadiol, wherein a ratio (A)/(B) of a mass of the (A) panaxatriol to a mass of the (B) protopanaxatriol is 1 or greater, and a ratio (C)/(D) of a mass of the (C) panaxadiol to a mass of the (D) protopanaxadiol is 1 or greater.

2012-10-04

20120252769

2-PHENYL-1-[4-(2-AMINOETHOXY)-BENZYL]-INDOLE AND ESTROGEN FORMULATIONS - The present invention relates to new formulations containing one or more estrogens and 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole compounds which are useful as estrogenic agents, as well as pharmaceutical compositions and methods of treatment utilizing these compounds, which have the general structures below:

IMPLANTS AND METHODS FOR TREATING INFLAMMATION-MEDIATED CONDITIONS OF THE EYE - Methods for treating inflammation-mediated conditions of the eye are described, comprising: implanting into the vitreous of the eye of an individual a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration equivalent to at least about 0.05 μg/ml dexamethasone within about 48 hours and maintains a concentration equivalent to at least about 0.03 μg/ml dexamethasone for at least about three weeks.

STEROID TETROL SOLID STATE FORMS - 2 - The invention relates to solid state forms of androst-5-ene-3α,7β,16β,17β-tetrol, formulations containing or prepared from such solid state forms and use of these materials for modulating unwanted inflammation including acute and chronic non-productive inflammation. The formulations can be used to prevent, treat or slow the progression of conditions related to autoimmunity and metabolic disorders such as arthritis, multiple sclerosis, ulcerative colitis, Type 1 diabetes and Type 2 diabetes.

PYRAZOLO PYRIMIDINE DERIVATIVES - The present invention relates to pyrazolo pyrimidine derivatives, to methods of preparing these, to combinations and pharmaceutical composition comprising these, and to their use in the treatment of diseases and disorders which may for example involve autoimmune diseases, angiogenesis, pain, and/or inflammatory diseases.

BICYCLIC PYRIDINES AND ANALOGS AS SIRTUIN MODULATORS - Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

2,3,4-BENZOTHIADIAZEPINE-2,2-DIOXIDE DERIVATIVES - Novel 2,3,4-benzothiadiazepines-2,2-dioxides and processes for the preparation thereof are disclosed. The compounds influence the central nervous system and may be used to treat or prevent Alzheimer's disease, Parkinson's disease or Huntington's disease, senile dementia not of the Alzheimer's type, vascular dementia, post-stroke dementia, Korsakoff's syndrome, Down's syndrome, schizophrenia, panic disorder, post-traumatic stress disorder, anxiety or depression.

2012-10-04

20120252785

STAUROSPORINE DERIVATIVES AS INHIBITORS OF FLT3 RECEPTOR TYROSINE KINASE ACTIVITY - The present invention relates to the use of staurosporines derivatives for the preparation of a drug for the treatment of diseases involving deregulated FLT3 receptor tyrosine kinase activity, especially for the curative and/or prophylactic treatment of leukemias and myelodysplastic syndromes, and to a method of treating diseases involving deregulated FLT3 receptor tyrosine kinase activity.

2012-10-04

20120252786

5HT2C RECEPTOR MODULATOR COMPOSITIONS AND METHODS OF USE - The present invention relates to a composition comprising phentermine and a selective 5HT-2C receptor agonist. In addition, the invention relates to a composition comprising phentermine and a selective 5HT-2C receptor agonist having Formula (I): or a pharmaceutically acceptable salt, solvate or hydrate thereof. These compositions are useful in pharmaceutical compositions whose use includes the treatment of obesity.

2012-10-04

20120252787

ADMINISTRATION OF AN ANTI-OBESITY COMPOUND TO INDIVIDUALS WITH RENAL IMPAIRMENT - The present disclosure relates to methods for weight management in an individual in need thereof by determining the level of renal sufficiency of the individual and prescribing or administering a therapeutically effective amount of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof to the individual, provided that the individual has a level of renal sufficiency selected from the group consisting of: no renal impairment, mild renal impairment, and moderate renal impairment. In addition, the disclosure relates to a method for selecting an individual for treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof from a plurality of individuals in need of weight management by determining the level of renal sufficiency of the individual and selecting the individual for treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof if the individual has a level of renal sufficiency selected from the group consisting of: no renal impairment, mild renal impairment, and moderate renal impairment.

Heterocyclic GTP Cyclohydrolase 1 Inhibitors For the Treatment of Pain - The present invention relates to the field of small molecule heterocyclic inhibitors of GTP cyclohydrolase (GCH-I), or a tautomer, prodrug, or pharmaceutically acceptable salt thereof. The invention also features pharmaceutical compositions of the compounds and the medical use of these compounds for the treatment or prevention of pain (e.g., inflammatory pain, nociceptive pain, functional pain, or neuropathic pain).

2012-10-04

20120252792

METHODS AND COMPOSITIONS FOR MODULATING RHO-MEDIATED GENE TRANSCRIPTION - The invention provides methods, compositions, and kits for the inhibition of members of the Rho GTPase family. Specifically, the invention provides methods, compositions and kits for the inhibition of RhoA and/or RhoC transcriptional signalling. The invention finds use in treatment of Rho-mediated disease states (e.g., tumor metastasis, inflammation, inflammatory disease), Rho-mediated biological conditions, and in cell signaling research.

2012-10-04

20120252793

INTRANASAL BENZODIAZEPINE PHARMACEUTICAL COMPOSITIONS - The present invention generally relates to intranasal pharmaceutical compositions comprising a benzodiazepine and methods of use thereof that can provide a therapeutic effect without a decrease in blood pressure and/or pulse after administration of the pharmaceutical composition.

2012-10-04

20120252795

ORAL LYSOPHILISATES CONTAINING PVP/VA - The present invention relates to novel oral pharmaceutical compositions in lyophilized form, in which the dissolution and the bioavailability of the active ingredient that they contain are improved. The compositions according to the invention comprise in particular a polyvinyl acetate/polyvinylpyrrolidone copolymer. The oral lyophilisates according to the invention are particularly suitable for the production of medicaments based on active ingredients which have low solubility or very low solubility in water or which are virtually insoluble in water.